Ionis Pharmaceuticals, Inc.
HealthcareNASDAQ:IONS · NASDAQ Global Select
-$0.55 today
Vol 1.84M · Avg 1.86M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-77.9%
avg -38.2%
ROIC
-12.0%
avg -5.7%
ROA
-10.8%
avg -6.0%
Analysis
ROA is currently the strongest return metric at -10.8% versus its period average of -6.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Brett Monia | Founder, Chief Executive Officer & Director | $3.47M | — | 65 | $242,662.00 | 0.15% |
Elizabeth L. Hougen | Executive Vice President of Finance & Chief Financial Officer | $1.60M | — | 64 | $16,348.00 | <0.01% |
Richard S. Geary | Strategic Consultant | $1.33M | — | 68 | $59,657.00 | 0.04% |
Brian Birchler | Executive Vice President of Corporate & Development Operations | $1.24M | — | 60 | $67,500.00 | 0.04% |
Eric E. Swayze | Executive Vice President of Research | $1.23M | — | 60 | $32,361.00 | 0.02% |
Patrick R. O'Neil | Executive Vice President, Chief Legal Officer, General Counsel & Corporate Secretary | $1.21M | — | 52 | $72,359.00 | 0.04% |
Kyle Jenne | Executive Vice President & Chief Global Product Strategy Officer | $804,966.00 | — | 49 | $23,713.00 | 0.01% |
C. Frank Bennett | Executive Vice President & Chief Scientific Officer | $651,639.00 | — | 69 | $165,643.00 | 0.10% |
Sujit K. Basu | Vice President & Head of Pharmaceutical Development | — | — | — | — | — |
Jonathan J. Birchall | Senior VP & Chief Commercial Officer | — | — | 56 | $7,940.00 | <0.01% |
Eugene Schneider | Executive Vice President, Chief Clinical Development & Operations Officer | — | — | 53 | $63,890.00 | 0.04% |
Rachel Carnes | Senior Vice President of Global Product Strategy | — | — | — | — | — |
Roger Lane | Senior Vice President of Clinical Development | — | — | — | — | — |
Darren Gonzales | Chief Accounting Officer & Senior Vice President | — | — | — | — | — |
D. Wade Walke | Senior Vice President of Investor Relations | — | — | — | — | — |
Cliff Ford | Senior VP of Intellectual Property | — | — | — | — | — |
Hala Mirza | Senior Vice President of Corporate Affairs & Patient Advocacy | — | — | — | — | — |
Tracy Berns | Senior Vice President and Chief Compliance & Quality Assurance Officer | — | — | — | — | — |
Charles G. Asare | Vice President & Head of Drug Safety | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
66
$68.48M
Net Sentiment
$68.48M
Net selling
Most Active
Baroldi Joseph
9 transactions
1–10 of 66
Analysis
Insiders reported 0 buys worth $0.00 and 66 sells worth $68.48M over the last 12 months. That adds up to net selling of $68.48M. Baroldi Joseph was the most active insider with 9 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A12 analysts |
| Revenue | N/A | N/A | +40.6% | +18.7% (15yr)9 analysts |
| Net Income | N/A | N/A | N/A | N/A9 analysts |
| EBIT | N/A | N/A | N/A | N/A9 analysts |
Analysis
Recent growth has been strongest in Revenue at +40.6% over three years. Forward estimates point to Revenue at +18.7% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$32.71B
Roivant Sciences Ltd.
NASDAQ:ROIV
$21.61B
Moderna, Inc.
NASDAQ:MRNA
$19.80B
Guardant Health, Inc.
NASDAQ:GH
$17.45B
Ascendis Pharma A/S
NASDAQ:ASND
$13.47B
Exelixis, Inc.
NASDAQ:EXEL
$13.35B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.08B
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
$11.08B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.86B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.81B
Who manages IONS?
Ionis Pharmaceuticals, Inc. (IONS) lists 19 active executives. The top listed executive is Sujit K. Basu, Vice President & Head of Pharmaceutical Development.
Are IONS insiders buying or selling?
Recent insider activity shows net selling of $66.78M.
Explore More
Continue the stock analysis
Jump to another research area for this company.